LABGENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,770 KRW | +0.73% |
|
+2.03% | -28.15% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With regards to fundamentals, the enterprise value to sales ratio is at 1846.83 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -28.15% | 149M | - | ||
| -18.58% | 8.15B | B+ | ||
| +47.25% | 3.82B | C+ | ||
| -8.58% | 2.47B | - | ||
| -38.71% | 2.46B | B- | ||
| -10.06% | 2.34B | B- | ||
| -5.44% | 1.88B | C- | ||
| -17.79% | 1.55B | A- | ||
| -40.78% | 1.21B | C+ | ||
| +6.69% | 1.11B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A084650 Stock
- Ratings LabGenomics Co., Ltd.
